New combo therapy shows promise for Hard-to-Treat leukemia
NCT ID NCT05441514
First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This early-stage trial tested the safety and best dose of two drugs (enasidenib and cobimetinib) given together to people whose acute myeloid leukemia (AML) had returned or stopped responding to treatment. Only patients with specific gene mutations (IDH2 and RAS) were included. The goal was to see if the combination could block cancer growth more effectively than either drug alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.